Fidarestat induces glycolysis of NK cells through decreasing AKR1B10 expression to inhibit hepatocellular carcinoma
The aldose reductase inhibitor Fidarestat has been noted to have efficacy in treating a variety of tumors. To define its role in hepatocellular carcinoma (HCC), we induced a HCC xenograft model in mice, which were treated with different doses of Fidarestat. The amounts of natural killer (NK) cells a...
Guardat en:
| Autors principals: | , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Elsevier
2021-12-01
|
| Col·lecció: | Molecular Therapy: Oncolytics |
| Matèries: | |
| Accés en línia: | http://www.sciencedirect.com/science/article/pii/S237277052100084X |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|